(VIANEWS) – AG Mortgage Investment Trust (MITT), Walker & Dunlop (WD), Regeneron Pharmaceuticals (REGN) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. AG Mortgage Investment Trust (MITT)

223.4% sales growth and 30.45% return on equity

AG Mortgage Investment Trust, Inc., a real estate investment trust, invests in a portfolio of residential mortgage-backed securities and credit investments in the United States.

AG Mortgage Investment Trust’s sales growth this year is anticipated to be 81.3% and 68.9% for next year.

Year-on-year quarterly revenue growth grew by 184.9%, now sitting on 114.36M for the twelve trailing months.

Volume

Today’s last reported volume for AG Mortgage Investment Trust is 370615 which is 2.07% above its average volume of 363091.

AG Mortgage Investment Trust’s sales growth for the next quarter is 223.4%. The company’s growth estimates for the ongoing quarter and the next is a negative 94.5% and negative -90.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.45%.

Volatility

AG Mortgage Investment Trust’s last day, last week, and last month’s current intraday variation average was 0.50%, 0.95%, and 0.79%, respectively.

AG Mortgage Investment Trust’s highest amplitude of average volatility was 2.45% (day), 2.29% (last week), and 2.28% (last month), respectively.

AG Mortgage Investment Trust’s Stock Yearly Top and Bottom Value

AG Mortgage Investment Trust’s stock is valued at $10.01 at 10:22 EST, way under its 52-week high of $14.88 and way higher than its 52-week low of $8.94.

AG Mortgage Investment Trust’s Moving Average

AG Mortgage Investment Trust’s worth is below its 50-day moving average of $10.72 and way under its 200-day moving average of $11.48.

2. Walker & Dunlop (WD)

32.4% sales growth and 21.53% return on equity

Walker & Dunlop, Inc., through its subsidiaries, originates, sells, and services a range of multifamily and other commercial real estate financing products and services for owners and developers of real estate in the United States.

Walker & Dunlop’s sales growth this year is expected to be 9.6% and 18.4% for next year.

Year-on-year quarterly revenue growth grew by 42%, now sitting on 1.2B for the twelve trailing months.

Volume

Today’s last reported volume for Walker & Dunlop is 246465 which is 101.63% above its average volume of 122235.

Walker & Dunlop’s sales growth for the next quarter is 32.4%. The company’s growth estimates for the ongoing quarter and the next is a negative 10.8% and 12.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.53%.

Volatility

Walker & Dunlop’s last day, last week, and last month’s current intraday variation average was 1.10%, 2.98%, and 1.62%, respectively.

Walker & Dunlop’s highest amplitude of average volatility was 3.43% (day), 4.25% (last week), and 2.87% (last month), respectively.

Walker & Dunlop’s Stock Yearly Top and Bottom Value

Walker & Dunlop’s stock is valued at $132.30 at 10:22 EST, way below its 52-week high of $156.77 and way above its 52-week low of $81.52.

Walker & Dunlop’s Moving Average

Walker & Dunlop’s value is way below its 50-day moving average of $147.37 and way above its 200-day moving average of $118.64.

3. Regeneron Pharmaceuticals (REGN)

18.3% sales growth and 51.09% return on equity

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.

Regeneron Pharmaceuticals’s sales growth this year is expected to be 56.3% and a negative 10.8% for next year.

Year-on-year quarterly revenue growth grew by 50.5%, now sitting on 13.36B for the twelve trailing months.

Volume

Today’s last reported volume for Regeneron Pharmaceuticals is 142616 which is 81.2% below its average volume of 758756.

Regeneron Pharmaceuticals’s sales growth for the next quarter is 18.3%. The company’s growth estimates for the current quarter and the next is 7.7% and 8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 51.09%.

Volatility

Regeneron Pharmaceuticals’s last day, last week, and last month’s current intraday variation average was 1.14%, 0.93%, and 1.03%, respectively.

Regeneron Pharmaceuticals’s highest amplitude of average volatility was 2.12% (day), 2.00% (last week), and 1.89% (last month), respectively.

Regeneron Pharmaceuticals’s Stock Yearly Top and Bottom Value

Regeneron Pharmaceuticals’s stock is valued at $614.21 at 10:22 EST, way under its 52-week high of $686.62 and way higher than its 52-week low of $441.00.

Regeneron Pharmaceuticals’s Moving Average

Regeneron Pharmaceuticals’s value is above its 50-day moving average of $610.79 and above its 200-day moving average of $567.66.

4. VALE (VALE)

17.4% sales growth and 29.06% return on equity

Vale S.A., together with its subsidiaries, produces and sells iron ore and iron ore pellets for use as raw materials in steelmaking in Brazil and internationally.

VALE’s sales growth this year is anticipated to be 55.9% and a negative 12.8% for next year.

Year-on-year quarterly revenue growth grew by 121.8%, now sitting on 246.58B for the twelve trailing months.

Volume

Today’s last reported volume for VALE is 44823200 which is 32.95% above its average volume of 33713500.

VALE’s sales growth for the next quarter is 17.4%. The company’s growth estimates for the current quarter and the next is 169.5% and 664.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.06%.

Volatility

VALE’s last day, last week, and last month’s current intraday variation average was 2.50%, 2.34%, and 2.03%, respectively.

VALE’s highest amplitude of average volatility was 3.17% (day), 2.77% (last week), and 2.38% (last month), respectively.

VALE’s Stock Yearly Top and Bottom Value

VALE’s stock is valued at $15.60 at 10:22 EST, way below its 52-week high of $23.18 and way higher than its 52-week low of $11.41.

VALE’s Moving Average

VALE’s worth is way higher than its 50-day moving average of $13.71 and way below its 200-day moving average of $19.03.

5. T. Rowe Price Group (TROW)

14.5% sales growth and 38.95% return on equity

T.

T. Rowe Price Group’s sales growth this year is expected to be 24.1% and 5.4% for next year.

Year-on-year quarterly revenue growth grew by 36.3%, now sitting on 7.08B for the twelve trailing months.

Volume

Today’s last reported volume for T. Rowe Price Group is 1977900 which is 79.79% above its average volume of 1100070.

T. Rowe Price Group’s sales growth is a negative 0% for the current quarter and 14.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 29.4% and 13.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 38.95%.

Volatility

T. Rowe Price Group’s last day, last week, and last month’s current intraday variation average was 3.20%, 2.12%, and 2.21%, respectively.

T. Rowe Price Group’s highest amplitude of average volatility was 2.52% (day), 3.16% (last week), and 3.32% (last month), respectively.

T. Rowe Price Group’s Stock Yearly Top and Bottom Value

T. Rowe Price Group’s stock is valued at $159.68 at 10:22 EST, way below its 52-week high of $224.56 and way above its 52-week low of $142.30.

T. Rowe Price Group’s Moving Average

T. Rowe Price Group’s value is way below its 50-day moving average of $206.90 and way under its 200-day moving average of $195.61.

6. Johnson & Johnson (JNJ)

10.4% sales growth and 26.81% return on equity

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide.

Johnson & Johnson’s sales growth this year is anticipated to be 14.1% and 4% for next year.

Year-on-year quarterly revenue growth grew by 27.1%, now sitting on 89.19B for the twelve trailing months.

Volume

Today’s last reported volume for Johnson & Johnson is 10499300 which is 40.9% above its average volume of 7451300.

Johnson & Johnson’s sales growth is a negative 0% for the current quarter and 10.4% for the next. The company’s growth estimates for the present quarter and the next is 7.3% and 19.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.81%.

Volatility

Johnson & Johnson’s last day, last week, and last month’s current intraday variation average was 0.23%, 0.47%, and 0.59%, respectively.

Johnson & Johnson’s highest amplitude of average volatility was 2.12% (day), 1.45% (last week), and 1.21% (last month), respectively.

Johnson & Johnson’s Stock Yearly Top and Bottom Value

Johnson & Johnson’s stock is valued at $164.87 at 10:22 EST, under its 52-week high of $179.92 and way higher than its 52-week low of $142.86.

Johnson & Johnson’s Moving Average

Johnson & Johnson’s value is above its 50-day moving average of $162.51 and under its 200-day moving average of $167.48.

Previous days news about Johnson & Johnson(JNJ)

  • According to Bloomberg Quint on Friday, 21 January, "One person boosted with the Johnson & Johnson shot and two receiving Pfizer suffered serious adverse effects potentially linked to the vaccine, but all recovered completely."
  • According to The New York Times on Saturday, 22 January, "The C.D.C. now recommends booster shots for everyone 12 years and older, five months after getting two doses of the mRNA vaccines made by Pfizer-BioNTech and Moderna, or two months after a single dose of the Johnson & Johnson vaccine."

7. Enbridge (ENB)

8.4% sales growth and 9.7% return on equity

Enbridge Inc. operates as an energy infrastructure company in Canada and the United States.

Enbridge’s sales growth this year is anticipated to be 6.7% and 5.5% for next year.

Year-on-year quarterly revenue growth grew by 37.6%, now sitting on 42.2B for the twelve trailing months.

Volume

Today’s last reported volume for Enbridge is 10729700 which is 89.45% above its average volume of 5663460.

Enbridge’s sales growth for the next quarter is 8.4%. The company’s growth estimates for the ongoing quarter and the next is 22.2% and 54.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.7%.

Volatility

Enbridge’s last day, last week, and last month’s current intraday variation average was 2.35%, 0.95%, and 0.76%, respectively.

Enbridge’s highest amplitude of average volatility was 2.97% (day), 1.69% (last week), and 1.32% (last month), respectively.

Enbridge’s Stock Yearly Top and Bottom Value

Enbridge’s stock is valued at $40.81 at 10:22 EST, below its 52-week high of $43.35 and way higher than its 52-week low of $28.39.

Enbridge’s Moving Average

Enbridge’s worth is below its 50-day moving average of $41.60 and higher than its 200-day moving average of $39.92.

8. Kinder Morgan (KMI)

6.8% sales growth and 5.61% return on equity

Kinder Morgan, Inc. operates as an energy infrastructure company in North America.

Kinder Morgan’s sales growth this year is expected to be 25.9% and a negative 12.1% for next year.

Year-on-year quarterly revenue growth grew by 67.8%, now sitting on 13.8B for the twelve trailing months.

Volume

Today’s last reported volume for Kinder Morgan is 19880700 which is 30.83% above its average volume of 15195300.

Kinder Morgan’s sales growth for the next quarter is 6.8%. The company’s growth estimates for the present quarter and the next is 14.3% and negative 0%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.61%.

Volatility

Kinder Morgan’s last day, last week, and last month’s current intraday variation average was 0.35%, 0.96%, and 0.97%, respectively.

Kinder Morgan’s highest amplitude of average volatility was 1.86% (day), 2.55% (last week), and 1.98% (last month), respectively.

Kinder Morgan’s Stock Yearly Top and Bottom Value

Kinder Morgan’s stock is valued at $17.37 at 10:22 EST, below its 52-week high of $19.29 and way above its 52-week low of $12.58.

Kinder Morgan’s Moving Average

Kinder Morgan’s worth is higher than its 50-day moving average of $17.27 and under its 200-day moving average of $17.49.

Previous days news about Kinder Morgan(KMI)

  • According to Bloomberg Quint on Wednesday, 19 January, "And big-oilproducers, shale drillers and pipeline operators alike-from Exxon Mobil Corp. to EQT Corp. to Kinder Morgan Inc.-can’t wait to offer it to them. "
  • According to Benzinga on Wednesday, 19 January, "• Kinder Morgan (NYSE:KMI) is estimated to report quarterly earnings at $0.25 per share on revenue of $3.58 billion."
  • According to Bloomberg Quint on Wednesday, 19 January, "The probe comes as major pipeline operator Kinder Morgan Inc. notified customers that it’s preparing for so-called freeze offs across gas fields when temperatures plunge in coming days."
  • Kinder morgan posts record annual profit on Texas deep freeze. According to Bloomberg Quint on Wednesday, 19 January, "Shares of Kinder Morgan have risen 9.9% this year, underperforming the S&P 500 Energy Index’s 16% gain."

LEAVE A REPLY

Please enter your comment!
Please enter your name here